3 results
Approved WMOCompleted
To assess the effect of AMG785 treatment for 12 months followed by alendronate treatment compared with alendronate on the incidence of clinical fracture and new vertebral fracture.
Approved WMOCompleted
Primary objective- To evaluate the efficacy of lenalidomide (RevlimidTM) in low/int-1 risk MDS with or without a treatment with Epo (NeoRecormonTM)/G-CSF (NeupogenTM) in terms of hematological improvement (HI) as defined by the modified response…
Approved WMORecruiting
To investigate if rhEPO has a positive effect on MRI/MRA parameters compared to infants with stroke without rhEPO collected from historical data.To investigate if rhEPO (3 dosages of 1000IU/kg/day) for perinatal stroke has no negative side-effects…